FI120081B - Mikrokapslar, förfarande för deras framställning, och deras användning - Google Patents
Mikrokapslar, förfarande för deras framställning, och deras användning Download PDFInfo
- Publication number
- FI120081B FI120081B FI962917A FI962917A FI120081B FI 120081 B FI120081 B FI 120081B FI 962917 A FI962917 A FI 962917A FI 962917 A FI962917 A FI 962917A FI 120081 B FI120081 B FI 120081B
- Authority
- FI
- Finland
- Prior art keywords
- microcapsules
- biodegradable
- water
- group
- microcapsules according
- Prior art date
Links
- 239000003094 microcapsule Substances 0.000 title claims abstract description 158
- 238000000034 method Methods 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims description 14
- 230000008569 process Effects 0.000 title claims description 11
- 239000000203 mixture Substances 0.000 claims abstract description 56
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 claims abstract description 41
- 150000002632 lipids Chemical class 0.000 claims abstract description 37
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229920002988 biodegradable polymer Polymers 0.000 claims abstract description 23
- 239000004621 biodegradable polymer Substances 0.000 claims abstract description 23
- 239000012528 membrane Substances 0.000 claims abstract description 20
- 229960001947 tripalmitin Drugs 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000013543 active substance Substances 0.000 claims abstract description 18
- 239000004094 surface-active agent Substances 0.000 claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 239000000725 suspension Substances 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 9
- 239000002872 contrast media Substances 0.000 claims abstract description 6
- 210000000056 organ Anatomy 0.000 claims abstract description 5
- 241001465754 Metazoa Species 0.000 claims abstract description 4
- 239000002775 capsule Substances 0.000 claims description 22
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 21
- 239000000194 fatty acid Substances 0.000 claims description 21
- 229930195729 fatty acid Natural products 0.000 claims description 21
- -1 cycloctane Chemical compound 0.000 claims description 20
- 150000004665 fatty acids Chemical class 0.000 claims description 19
- 125000005456 glyceride group Chemical group 0.000 claims description 19
- 239000007787 solid Substances 0.000 claims description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 12
- 239000002609 medium Substances 0.000 claims description 11
- 150000003626 triacylglycerols Chemical class 0.000 claims description 11
- 229930182558 Sterol Natural products 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 9
- 235000003702 sterols Nutrition 0.000 claims description 9
- 238000012285 ultrasound imaging Methods 0.000 claims description 9
- 239000008346 aqueous phase Substances 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 150000003432 sterols Chemical class 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- 150000003904 phospholipids Chemical class 0.000 claims description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000012071 phase Substances 0.000 claims description 6
- 239000012736 aqueous medium Substances 0.000 claims description 5
- 229920001400 block copolymer Polymers 0.000 claims description 5
- 239000007764 o/w emulsion Substances 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 5
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000003791 organic solvent mixture Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229960005205 prednisolone Drugs 0.000 claims description 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 4
- 239000001993 wax Substances 0.000 claims description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 3
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims description 3
- UGCSPKPEHQEOSR-UHFFFAOYSA-N 1,1,2,2-tetrachloro-1,2-difluoroethane Chemical compound FC(Cl)(Cl)C(F)(Cl)Cl UGCSPKPEHQEOSR-UHFFFAOYSA-N 0.000 claims description 3
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 claims description 3
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 3
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 3
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 239000007972 injectable composition Substances 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 239000003021 water soluble solvent Substances 0.000 claims description 3
- 239000008096 xylene Substances 0.000 claims description 3
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 2
- 241001553178 Arachis glabrata Species 0.000 claims description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 2
- 235000018262 Arachis monticola Nutrition 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 2
- 229960001805 chloramphenicol palmitate Drugs 0.000 claims description 2
- PXKHGMGELZGJQE-ILBGXUMGSA-N chloramphenicol palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 PXKHGMGELZGJQE-ILBGXUMGSA-N 0.000 claims description 2
- 150000001924 cycloalkanes Chemical class 0.000 claims description 2
- 238000009826 distribution Methods 0.000 claims description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 230000001804 emulsifying effect Effects 0.000 claims description 2
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical class CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 150000008282 halocarbons Chemical class 0.000 claims description 2
- 239000000193 iodinated contrast media Substances 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 150000002596 lactones Chemical class 0.000 claims description 2
- 235000020232 peanut Nutrition 0.000 claims description 2
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 2
- 239000011877 solvent mixture Substances 0.000 claims description 2
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims 1
- 235000021360 Myristic acid Nutrition 0.000 claims 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 229950005499 carbon tetrachloride Drugs 0.000 claims 1
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 abstract description 14
- 238000001704 evaporation Methods 0.000 abstract description 6
- 238000004108 freeze drying Methods 0.000 abstract description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 5
- 239000007864 aqueous solution Substances 0.000 abstract description 4
- 238000003384 imaging method Methods 0.000 abstract description 4
- 239000003981 vehicle Substances 0.000 abstract description 4
- 239000008365 aqueous carrier Substances 0.000 abstract 1
- 239000011363 dried mixture Substances 0.000 abstract 1
- 239000007762 w/o emulsion Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 238000007667 floating Methods 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000000839 emulsion Substances 0.000 description 11
- 239000004005 microsphere Substances 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 238000006065 biodegradation reaction Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000002961 echo contrast media Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229940067631 phospholipid Drugs 0.000 description 5
- 229920001983 poloxamer Polymers 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 229960002372 tetracaine Drugs 0.000 description 4
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 4
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- 108010020346 Polyglutamic Acid Proteins 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229960003529 diazepam Drugs 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960004275 glycolic acid Drugs 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- 229920002643 polyglutamic acid Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristoyl-sn-glycerol Natural products CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 3
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 2
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 2
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 2
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 2
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000002635 electroconvulsive therapy Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229960000780 iomeprol Drugs 0.000 description 2
- NJKDOADNQSYQEV-UHFFFAOYSA-N iomeprol Chemical compound OCC(=O)N(C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NJKDOADNQSYQEV-UHFFFAOYSA-N 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 2
- 229940058690 lanosterol Drugs 0.000 description 2
- 238000012886 linear function Methods 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- KMEHEQFDWWYZIO-UHFFFAOYSA-N triacontyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC KMEHEQFDWWYZIO-UHFFFAOYSA-N 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 239000003799 water insoluble solvent Substances 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical class CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- KYHQZNGJUGFTGR-LURJTMIESA-N 7-[(2s)-2-hydroxypropyl]-1,3-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C[C@@H](O)C KYHQZNGJUGFTGR-LURJTMIESA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100494773 Caenorhabditis elegans ctl-2 gene Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101100112369 Fasciola hepatica Cat-1 gene Proteins 0.000 description 1
- 150000000921 Gadolinium Chemical class 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000002616 MRI contrast agent Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 101100005271 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-1 gene Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- MXZROTBGJUUXID-UHFFFAOYSA-I [Gd+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)C(C([O-])=O)COCC1=CC=CC=C1 Chemical compound [Gd+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)C(C([O-])=O)COCC1=CC=CC=C1 MXZROTBGJUUXID-UHFFFAOYSA-I 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000013007 heat curing Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 229960004647 iopamidol Drugs 0.000 description 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960004624 perflexane Drugs 0.000 description 1
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960004767 proxyphylline Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 229960003853 ultrasound contrast media Drugs 0.000 description 1
- 229940072690 valium Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Physiology (AREA)
- Radiology & Medical Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (30)
1. Fas ta mikrokapsiarsoin har en medelstorlek av 1 μπι - 1000 |±m och som har en bionedbrytfoar membran, som 5 inkapslar en luft- ellei, gaskärna, känneteclnade därsv, att membranen omfattar minst 25 vikt-% av en eller flera, i vatten olösliga bionedbrytbara lipider, som är fasta vid rumstemperatur ooh som är valda ur gruppen mono-, di- och tri glycerider, fettsyror med minst 12 kolatomer 10 och estrar av dessa fettsyror, steroler,, vax och bland- hingar av dessa.
2. Mikrokapsiar enligt patentkrav 1, känne-tecknade tecknade därav, att glyceriden är mono-, di-eller trimyristin, -palmitin, -stearin, eller blandningar 15 av dessa ooh företrädesvis fcripalmitin eller tristearin.
3. Mikrokapsiar enligt patentkrav 1, kanne - tecknade därav, att fettsyrorna är valda ur gruppen jordnöts-, behen-, palmitin-, stearin-, sebacin-, myristun- , och erukasyra, och företrädesvis ur gruppen stearin-, 20 palmitin-, sebacin- och myristinsyra.
4. Mikrokapsiar enligt patentkrav 1, k anne- tecknade därav, att sterolen är vald ur gruppen koles-terol, fytosteroi, lanosterol, ergosterol, och estrar av steroler med fettsyror enligt patentkrav 3, och är fcre- 25 trädesvis kolesterol.
5. Mikrokapsiar enligt patentkrav 1, kanne- t e c k n a d e därav, att membranen är ätminstone delvis kristallin eller semikristallin.
6. Mikrokapsiar enligt patentkrav 1, k ä n n e - 30 tecknade därav, att membranen omfattar ytterligare högst 75 vikt-% toionedbrytbara polymerer.
7. Mikrokapsiar enligt patentkrav 6, kännetecknade därav, att membranen omfattar högst 50 vikt-%, företrädesvis högst 20 vikt-% och mera fördelaktigt högst 10 vikt-% 35 bionedbrytbara polymerer. 29
8. Mikrokapslar enligt patentkrav 1, 2 eller 3, k a n n e t e c k n a d e därav, att mikrokapslarna har en ge-nomsnittlig storieksfördelning 0,1 - 100 μτα.
9. Mikrokapslar enligt patentkrav 1, 2 eller 3, 5 kännetecknade därav, att mikrokapslarna är porösa och har en porositet av 20 - 2 000 run. 1-0» Mikrokapslar enligt patentkrav 1, känne tecknade därav, att mikrokapslarna är i'Gke^s.axnmansm^l-· tande, toria och ögohblickligen dispergerbara i ett väts-10 keformigt medium.
11. Mikrokapslar enligt patentkrav 10, känne tecknade därav, att mikrokapslarna omfatcar ytterliga-re ett äterdispergeringsmedel.
12. Mikrokapslar enligt patentkrav 11, kanne- 15 tecknade därav, att aterdispergeringsmedlet är valt ur gruppen albumin, polyvinylalkohol och polyetylenglykol.
13. Mikrokapslar enligt patentkrav 6 eller 7, kännetecknade därav, att den bionedbrytbafa polyme-ren är vald ur gruppen pol yarainosvror, polylaktider och 20 polyglykolider och kopolymerer av dessa, kopolymerer av laktider och laktoner, polypeptider, poly(orto)estrar, po~ lydioxanon, poly-p-aminoketoner, polyfosfazener, polyan-hydrider, polyhydroxibutvrat och polyalkyl(cyan)akrylater,
14. Mikrokapslar enligt nagot av föregäende pa- 25 tentkrav, kännetecknade därav, att mikrokapslarna omfattar ytterligare ett ytaktivt medel, som är valt ur gruppen polyoxietylen-polyoxipropylen-block-kopolymerer och fosfolipider.
15. Mikrokapslar enligt nägot av föregäende pa- 30 tentkrav, klnne t ecknade därav, att membranen omf attar ytterligare ett lipofilt aktivt medel.
16. Mikrokapslar enligt patentkrav 15, kännetecknade därav, att det lipoilla aktiva medlet är valt ur gruppen vitamin E, prednisolon, kloramfenikolpalmitat 35 och salbutamol. il 30
17. Mikrokapslar enligt patentkrav 1 - 15, k anne t e c k n a ά e därav, att kärnan omfattar ett icke-jpniskt joderat kontragtmedel eller MRl-kontrastmedel.
18. Mikrokapslar enligt patentkrav 1 - IS:, kan-5 netecknade därav, att kärnan omfattar insulin.
19. Förfarande för framställning av ett kontrast- medel, k ä n n e t ;e c k n a t därav, att mikrokapslar enligt patentkrav 17 suspenderas i en fysiologiskt godtagbar mediumia s .
20. Injekterbar komposition, kanneteeknad därav, att den innehäller en suspension av en effektiv mängd av mikrokapslar enligt nägot av patentkraven 1 - 18 i ett farmaceutiskt godtagbart medium med konventionella ti 1.1-satsmedel ooh stabilisatorer- 15 21. Förfarande för framställning av fas ta·, mikrokapslar enligt patentkraven 1 - 16 , k ä n n e t e c k n a t där av, att det omfattar s teg, där: man: a) löser en bxonedbrytbar lipid och eventuellt en bxonedbrytbar polymer i ett lösningsmedel eller lösnings- 20 medelsblandning, b) blandar med en vattenfas, c) emulgerar blandningen med för bildande av en oija-i-va11en-emu1si on, d) tiilsätter ett äterdispergeringsmedel, 25 e) nedfryser, f) lyofiliserar för bildande av ett pulver inne-häilande semisfäriskä eller sfäriska mikrokapslar, g) dispergerar pulvret i ett vattenbaserat medium, h} separerar mlkr okaps lama inhehällande luft el- 30 ler gas medelst dekantering frän en rest, och i) torkar de tillvaratagna mikrokapslama,
22. Förfarande enligt patentkrav 21, kanne tecknafc därav, att en del av det organiska lösnings-medlet avdunstas efter bildande av vatten-i-olja-emulsio- 35 nen. 31
23. Förfarande enligt pa tent kr av 21, kanne teckn at därav, att lösningsmedelsblanänirigen är en blandning av vattenlösliga och i vatten olösliga organiska lösningsmedel. 5 24. Förfarande enligt patent, kr av 23, kan ne tecknat därav, att det i vatteri olösliga lösnings-medlet är vai t ur gruppen alkanen , cykloalkanex:, ar omat is kä korvaten, etrar och halogenerade koIvaten.
25. Förfarande enligt patent kr av 24, kän- 10. e t e c k n a t därav, att lösningsmedlet är vai t ur gruppen toinen, xylen, cyklooktan, cyklohexan, kloroform, tetra-klormetan, difluortetrakloretan, dibutyleter, diisopropy-leter, isobutylmetylkaton och blandningar därav.
26. Förfarande enligt patentkrav 21, k ä n - 15 ne teckn at däräv, att mikrokapslarna ofattar ytterliga- re ett ytaktivt medel, som är valt ur gruppen gruppen po-lyoxietylen-polyoxipropylen-block-kopolyinerer och fosfoli-pider.
27. Förfarande enligt patentkrav 21, kän- 20 ne tecknat därav, att ett lipofilt aktivt sätts tili lösningen av lipiderna fore blandning med vattenfasen.
28. Mikrokapslar enlig patentkraven 1 -· 14 för användning ultraljudsavbildrling av organ i mänsko- eller dj urkropp.
29. Användning av mikrokapslar enligt patentkrav 1 - 18 för framställning av injekterbara, terapeutiskt ef~ fektiva kotipos i t ioner.
30. Användning av mikrokapslar enligt patentkrav 1 - 14 för framställning av medel för ultraljudsavbild-30 ning.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94810660 | 1994-11-22 | ||
EP94810660 | 1994-11-22 | ||
IB9501029 | 1995-11-21 | ||
PCT/IB1995/001029 WO1996015815A1 (en) | 1994-11-22 | 1995-11-21 | Microcapsules, method of making and their use |
Publications (3)
Publication Number | Publication Date |
---|---|
FI962917A0 FI962917A0 (sv) | 1996-07-19 |
FI962917A FI962917A (sv) | 1996-07-19 |
FI120081B true FI120081B (sv) | 2009-06-30 |
Family
ID=8218339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI962917A FI120081B (sv) | 1994-11-22 | 1996-07-19 | Mikrokapslar, förfarande för deras framställning, och deras användning |
Country Status (20)
Country | Link |
---|---|
US (2) | US6333021B1 (sv) |
EP (1) | EP0755270B1 (sv) |
JP (1) | JP4202414B2 (sv) |
KR (1) | KR100416163B1 (sv) |
CN (1) | CN1066964C (sv) |
AT (1) | ATE337795T1 (sv) |
AU (1) | AU709240B2 (sv) |
CA (1) | CA2178602C (sv) |
CZ (1) | CZ291178B6 (sv) |
DE (1) | DE69535203T2 (sv) |
ES (1) | ES2271947T3 (sv) |
FI (1) | FI120081B (sv) |
HU (1) | HU226896B1 (sv) |
IL (1) | IL116081A (sv) |
MX (1) | MX9602697A (sv) |
NO (1) | NO315692B1 (sv) |
PL (1) | PL182989B1 (sv) |
RU (1) | RU2139046C1 (sv) |
WO (1) | WO1996015815A1 (sv) |
ZA (1) | ZA959941B (sv) |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5820850A (en) * | 1995-06-07 | 1998-10-13 | Molecular Biosystems, Inc. | Gas-filled amino acid block co-polymer microspheres useful as ultrasound contrast agents |
US6582392B1 (en) | 1998-05-01 | 2003-06-24 | Ekos Corporation | Ultrasound assembly for use with a catheter |
US6045777A (en) * | 1997-06-30 | 2000-04-04 | Acusphere, Inc. | Method for enhancing the echogenicity and decreasing the attenuation of microencapsulated gases |
TR200000812T2 (tr) * | 1997-09-30 | 2001-07-23 | Eli Lilly And Company | 2-metil-tieno- benzodiazepin formülasyonu. |
US6423345B2 (en) | 1998-04-30 | 2002-07-23 | Acusphere, Inc. | Matrices formed of polymer and hydrophobic compounds for use in drug delivery |
AU4917900A (en) * | 1999-05-07 | 2000-11-21 | Pharmasol Gmbh | Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same |
US6310014B1 (en) * | 1999-10-05 | 2001-10-30 | Phyzz Inc. | Personal and household care compositions |
US7109167B2 (en) | 2000-06-02 | 2006-09-19 | Bracco International B.V. | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
AU2002253454A1 (en) | 2001-04-06 | 2002-10-21 | Bracco Research S.A. | Method for improved measurement of local physical parameters in afluid-filled cavity |
NZ529544A (en) * | 2001-05-31 | 2006-11-30 | Skyepharma Inc | Encapsulation of nanosuspensions in liposomes and microspheres |
CN1308375C (zh) * | 2001-06-01 | 2007-04-04 | 安斯泰来制药欧洲有限公司 | 类脂-聚合物轭合物组合物 |
EP1275378B1 (en) | 2001-07-10 | 2009-04-15 | Canon Kabushiki Kaisha | Particulate construct comprising polyhydroxyalkanoate and method for producing it |
JP4850390B2 (ja) | 2001-10-19 | 2012-01-11 | アイデックス ラボラトリーズ インコーポレイテッド | 薬理学的に活性な化合物の制御送達のための注射用組成物 |
US6946137B2 (en) | 2001-10-19 | 2005-09-20 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
US6808715B2 (en) * | 2001-11-09 | 2004-10-26 | Or-Le-Or Ltd. | Wrinkle cream |
IL162001A0 (en) * | 2001-11-14 | 2005-11-20 | Alza Corp | Catheter injectable depot compositions and uses thereof |
US20070196415A1 (en) * | 2002-11-14 | 2007-08-23 | Guohua Chen | Depot compositions with multiple drug release rate controls and uses thereof |
BR0206984A (pt) * | 2001-11-14 | 2004-02-03 | Alza Corp | Composições de depósito injetáveis e uso destas |
ATE520362T1 (de) | 2001-12-03 | 2011-09-15 | Ekos Corp | Katheter mit mehreren ultraschall-abstrahlenden teilen |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
AU2003213730A1 (en) | 2002-03-01 | 2003-09-16 | Bracco International B.V. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
WO2004065621A1 (en) | 2002-03-01 | 2004-08-05 | Dyax Corp. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
CN1656234B (zh) * | 2002-03-20 | 2012-02-01 | 创新生物公司 | 包囊化核酸扩增反应混合物的微胶囊及其作为反应隔间进行平行反应的用途 |
US8226629B1 (en) | 2002-04-01 | 2012-07-24 | Ekos Corporation | Ultrasonic catheter power control |
US7607436B2 (en) * | 2002-05-06 | 2009-10-27 | The Research Foundation Of State University Of New York | Methods, devices and formulations for targeted endobronchial therapy |
US7334580B2 (en) * | 2002-05-07 | 2008-02-26 | Smaldone Gerald C | Methods, devices and formulations for targeted endobronchial therapy |
EP1515768B1 (en) | 2002-05-07 | 2013-11-06 | The State University of New York at Stony Brook | Devices for targeted endobronchial therapy |
US6919068B2 (en) * | 2002-05-17 | 2005-07-19 | Point Biomedical Corporation | Method of preparing gas-filled polymer matrix microparticles useful for echographic imaging |
US20030215394A1 (en) * | 2002-05-17 | 2003-11-20 | Short Robert E. | Microparticles having a matrix interior useful for ultrasound triggered delivery of drugs into the bloodstream |
US20030225448A1 (en) | 2002-05-28 | 2003-12-04 | Scimed Life Systems, Inc. | Polar radiopaque marker for stent |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
GB2399084B (en) * | 2002-07-30 | 2007-01-31 | Univ Liverpool | Porous beads and method of production thereof |
US8252303B2 (en) * | 2002-07-31 | 2012-08-28 | Durect Corporation | Injectable depot compositions and uses thereof |
NZ537953A (en) * | 2002-07-31 | 2007-02-23 | Alza Corp | Injectable multimodal polymer depot compositions and uses thereof |
CN100381463C (zh) * | 2002-09-18 | 2008-04-16 | 中国人民解放军免疫学研究所 | 用于生产治疗用乙型肝炎疫苗或药物的免疫原及其制备方法和用途 |
US9364569B2 (en) * | 2003-02-04 | 2016-06-14 | Bracco Suisse S.A. | Ultrasound contrast agents and process for the preparation thereof |
US20070128117A1 (en) * | 2003-02-04 | 2007-06-07 | Bracco International B.V. | Ultrasound contrast agents and process for the preparation thereof |
EP2284180B1 (en) | 2003-03-03 | 2015-09-09 | Dyax Corp. | Uses of peptides that specifically bind HGF receptor (cMET) |
US20040185108A1 (en) * | 2003-03-18 | 2004-09-23 | Short Robert E. | Method of preparing gas-filled polymer matrix microparticles useful for delivering drug |
ITFI20030077A1 (it) * | 2003-03-26 | 2004-09-27 | Actis Active Sensors S R L | Metodo per l'indagine ecografica tramite mezzi di contrasto |
US7439268B2 (en) * | 2003-07-18 | 2008-10-21 | Idexx Laboratories | Compositions containing prodrugs of florfenicol and methods of use |
US20050049210A1 (en) * | 2003-08-27 | 2005-03-03 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
CA2543296A1 (en) | 2003-10-31 | 2005-05-12 | Point Biomedical Corporation | Reconstitutable microsphere compositions useful as ultrasonic contrast agents |
AU2004308757B2 (en) * | 2003-12-22 | 2010-06-17 | Bracco Suisse S.A. | Assembly of gas-filled microvesicle with active component for contrast imaging |
EP1701745B1 (en) * | 2003-12-22 | 2014-12-10 | Bracco Suisse S.A. | Gas-filled microvesicle assembly for contrast imaging |
GB0401950D0 (en) * | 2004-01-28 | 2004-03-03 | Unilever Plc | Porous bodies and method of production thereof |
US7341569B2 (en) | 2004-01-30 | 2008-03-11 | Ekos Corporation | Treatment of vascular occlusions using ultrasonic energy and microbubbles |
US10335757B2 (en) * | 2004-03-05 | 2019-07-02 | Specialty Earth Sciences | Process for making environmental reactant(s) |
US7431849B1 (en) * | 2004-03-05 | 2008-10-07 | Specialty Earth Sciences Llc | Encapsulated reactant and process |
US8012457B2 (en) | 2004-06-04 | 2011-09-06 | Acusphere, Inc. | Ultrasound contrast agent dosage formulation |
GB2417080B (en) | 2004-08-13 | 2008-05-21 | Stichting Tech Wetenschapp | Intravascular ultrasound techniques |
CA2575677C (en) * | 2004-08-18 | 2013-01-22 | Bracco Research Sa | Gas-filled microvesicles composition for contrast imaging |
US7282487B2 (en) * | 2004-10-28 | 2007-10-16 | Idexx Laboratories | Method for treating bacterial infections in horses or pigs with tilmicosin |
US20060142234A1 (en) * | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
JP4940152B2 (ja) | 2005-01-05 | 2012-05-30 | イーライ リリー アンド カンパニー | パモ酸オランザピン二水和物 |
EP1714642A1 (en) * | 2005-04-18 | 2006-10-25 | Bracco Research S.A. | Pharmaceutical composition comprising gas-filled microcapsules for ultrasound mediated delivery |
JP4680012B2 (ja) * | 2005-09-05 | 2011-05-11 | 株式会社松風 | 半球状中空マイクロカプセル |
EP1797919A1 (en) * | 2005-12-16 | 2007-06-20 | Bracco Research S.A. | Liquid transfer device for medical dispensing containers |
US20070265560A1 (en) | 2006-04-24 | 2007-11-15 | Ekos Corporation | Ultrasound Therapy System |
CA2659645C (en) * | 2006-08-01 | 2015-06-30 | Martijn E. Frijlink | Pulse inversion sequences for nonlinear imaging |
US8093261B2 (en) | 2006-10-24 | 2012-01-10 | The Johns Hopkins University | Rapid release mini-tablets provide analgesia in laboratory animals |
JP2008120780A (ja) * | 2006-11-13 | 2008-05-29 | Kazutoyo Kawasaki | 胃部検診用造影剤 |
US20080305175A1 (en) * | 2006-11-30 | 2008-12-11 | Agency For Science, Technology And Research | Micro-Container |
EP2117603A2 (en) * | 2006-12-19 | 2009-11-18 | Bracco International B.V. | Targeting and therapeutic compounds and gas-filled microvesicles comprising said compounds |
US10182833B2 (en) | 2007-01-08 | 2019-01-22 | Ekos Corporation | Power parameters for ultrasonic catheter |
JP2008199905A (ja) * | 2007-02-16 | 2008-09-04 | Snow Brand Milk Prod Co Ltd | 乳酸菌生残性向上剤 |
FR2917291B1 (fr) * | 2007-06-14 | 2009-09-18 | Cooperative Bretonne D Insemin | Microcapsules contenant des spermatozoides de mammiferes, dose d'insemination les contenant et un porcede pour leur obtention |
PL2170181T3 (pl) | 2007-06-22 | 2014-08-29 | Ekos Corp | Sposób i aparat do leczenia wylewów wewnątrzczaszkowych |
EP2476703A1 (en) | 2011-01-14 | 2012-07-18 | Bracco Imaging S.p.A | Human antibodies cross-reacting with a bacterial and a self antigen from atherosclerotic plaques |
US7550625B2 (en) * | 2007-10-19 | 2009-06-23 | Idexx Laboratories | Esters of florfenicol |
EP2090322A1 (en) | 2008-02-18 | 2009-08-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fsh receptor ligands for diagnosis and therapy of cancer |
GB0811856D0 (en) * | 2008-06-27 | 2008-07-30 | Ucl Business Plc | Magnetic microbubbles, methods of preparing them and their uses |
JP5681626B2 (ja) * | 2008-07-14 | 2015-03-11 | ポリーペイド リミテッドPolypid Ltd. | 徐放性薬剤キャリア組成物 |
EP2147684A1 (en) | 2008-07-22 | 2010-01-27 | Bracco Imaging S.p.A | Diagnostic Agents Selective Against Metalloproteases |
EP2346532B1 (en) * | 2008-10-07 | 2020-10-07 | Bracco Suisse SA | Targeting construct comprising anti-polymer antibody and microvesicles binding to the same |
US20110045095A1 (en) * | 2008-10-08 | 2011-02-24 | The Regents Of The University Of California | Polymer-phospholipid shelled microbubbles |
EP2376145B1 (en) | 2008-12-16 | 2013-10-16 | Bracco Suisse SA | Device for bolus administration |
EP2453877B1 (en) | 2009-07-14 | 2019-05-08 | Polypid Ltd. | Sustained-release drug carrier composition |
ES2825802T3 (es) * | 2009-10-16 | 2021-05-17 | Lifecare Innovations Pvt Ltd | Formulación de anfotericina liposomal que comprende colesterol para tratar infecciones fúngicas |
EP2525778B1 (en) | 2010-01-19 | 2018-08-01 | Polypid Ltd. | Sustained-release nucleic acid matrix compositions |
MX354124B (es) | 2010-04-30 | 2018-02-14 | Hrd Corp | Aplicacion de alto cizallamiento en terapia medica. |
US8888736B2 (en) | 2010-04-30 | 2014-11-18 | H R D Corporation | High shear application in medical therapy |
PL2575448T3 (pl) * | 2010-06-07 | 2019-04-30 | Dow Agrosciences Llc | Zawiesiny mikrokapsułek zawierające wysokie poziomy substancji czynnych rolniczo |
CA2806639C (en) | 2010-08-09 | 2020-10-20 | Bracco Suisse Sa | Targeted gas-filled microvesicles |
CN103269717B (zh) | 2010-12-24 | 2016-08-03 | 博莱科瑞士股份有限公司 | 气体填充微囊泡用作疫苗 |
EP2474327A1 (en) | 2011-01-07 | 2012-07-11 | RWTH Aachen | Microdosing of ultrasound contrast agents |
WO2012095516A1 (en) | 2011-01-14 | 2012-07-19 | Bracco Imaging Spa | Human antibodies cross-reacting with a bacterial and a self antigen from atherosclerotic plaques |
EP2545908A1 (en) | 2011-07-11 | 2013-01-16 | RWTH Aachen | Medium for microbubbles or microparticles and preparation thereof |
WO2013151682A1 (en) | 2012-04-06 | 2013-10-10 | Children's Medical Center Corporation | Process for forming microbubbles with high oxygen content and uses thereof |
RU2502510C1 (ru) * | 2012-04-24 | 2013-12-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Курская государственная сельскохозяйственная академия имени профессора И.И. Иванова Министерства сельского хозяйства Российской Федерации | Способ получения микрокапсул лекарственных препаратов группы цефалоспоринов в конжаковой камеди в четыреххлористом углероде |
RU2525158C2 (ru) * | 2012-05-18 | 2014-08-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Курская государственная сельскохозяйственная академия имени профессора И.И. Иванова Министерства сельского хозяйства Российской Федерации | Способ получения микрокапсул лекарственных препаратов группы цефалоспоринов в конжаковой камеди в толуоле |
RU2514056C2 (ru) * | 2012-08-21 | 2014-04-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Курская государственная сельскохозяйственная академия имени профессора И.И. Иванова Министерства сельского хозяйства Российской Федерации | Способ инкапсуляции фенбендазола |
US20160067276A1 (en) * | 2013-03-15 | 2016-03-10 | Children's Medical Center Corporation | Hollow particles encapsulating a biological gas and methods of use |
EP2968825A4 (en) | 2013-03-15 | 2016-09-07 | Childrens Medical Center | GAS STABILIZED PARTICLES AND METHODS OF USE |
AU2014230447A1 (en) | 2013-03-15 | 2015-09-17 | Westfaelische Wilhelms-Universitaet Muenster | Detection of acute renal allograft rejection |
CN103349948B (zh) * | 2013-06-21 | 2015-05-27 | 江南大学 | 一种植物甾烷醇微胶囊化方法 |
BR112015032732B1 (pt) | 2013-07-03 | 2022-05-17 | Bracco Suisse S.A. | Sistema para tratamento ultrassônico de acidente vascular cerebral |
US20160303242A1 (en) | 2013-12-09 | 2016-10-20 | Durect Corporation | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same |
RU2557950C2 (ru) * | 2013-12-17 | 2015-07-27 | Александр Александрович Кролевец | Способ получения микрокапсул антиоксидантов |
RU2564890C1 (ru) * | 2014-05-20 | 2015-10-10 | Александр Александрович Кролевец | Способ получения нанокапсул антибиотиков в конжаковой камеди |
RU2577298C1 (ru) * | 2014-10-01 | 2016-03-10 | Общество с ограниченной ответственностью "МедКонтрастСинтез" (ООО "МедКонтрастСинтез") | Гепатотропное магнитно-резонансное средство |
RU2596485C1 (ru) * | 2015-02-24 | 2016-09-10 | Александр Александрович Кролевец | Способ получения нанокапсул креатина в геллановой камеди |
RU2591800C1 (ru) * | 2015-04-08 | 2016-07-20 | Александр Александрович Кролевец | Способ получения нанокапсул экстракта зеленого чая |
RU2591802C1 (ru) * | 2015-04-27 | 2016-07-20 | Александр Александрович Кролевец | Способ получения нанокапсул экстракта зеленого чая |
RU2599843C1 (ru) * | 2015-05-19 | 2016-10-20 | Александр Александрович Кролевец | Способ получения нанокапсул экстракта зеленого чая в пектине |
WO2016201136A1 (en) | 2015-06-10 | 2016-12-15 | Ekos Corporation | Ultrasound catheter |
EP3386589B1 (en) | 2015-12-09 | 2022-02-09 | Koninklijke Philips N.V. | Interleaved beam pattern for sonothrombolysis and other vascular acoustic resonator mediated therapies |
US11370826B2 (en) | 2016-02-09 | 2022-06-28 | Bracco Suisse Sa | Recombinant chimeric protein for selectins targeting |
US10647045B1 (en) | 2016-11-03 | 2020-05-12 | Specialty Earth Sciences, Llc | Shaped or sized encapsulated reactant and method of making |
WO2018160752A1 (en) | 2017-02-28 | 2018-09-07 | Children's Medical Center Corporation | Stimuli-responsive particles encapsulating a gas and methods of use |
KR20220140711A (ko) | 2020-01-13 | 2022-10-18 | 듀렉트 코퍼레이션 | 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법 |
WO2023137224A2 (en) * | 2022-01-17 | 2023-07-20 | Isp Investments Llc | Biodegradable microcapsules with improved storage stability, process for preparing the same and method of use thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
AU636481B2 (en) | 1990-05-18 | 1993-04-29 | Bracco International B.V. | Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography |
US5215680A (en) * | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
NZ244147A (en) * | 1991-09-03 | 1994-09-27 | Hoechst Ag | Echogenic particles which comprise a gas and at least one shaping substance, and their use as diagnostic agents |
DE4232755A1 (de) * | 1992-09-26 | 1994-03-31 | Schering Ag | Mikropartikelpräparationen aus biologisch abbaubaren Mischpolymeren |
HU221308B1 (en) * | 1992-10-26 | 2002-09-28 | Sanol Arznei Schwarz Gmbh | Process for producing microcapsules |
NZ262679A (en) * | 1993-02-22 | 1997-08-22 | Vivorx Pharmaceuticals Inc | Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell |
-
1995
- 1995-11-08 US US08/555,147 patent/US6333021B1/en not_active Expired - Fee Related
- 1995-11-21 CZ CZ19962140A patent/CZ291178B6/cs not_active IP Right Cessation
- 1995-11-21 JP JP51671596A patent/JP4202414B2/ja not_active Expired - Fee Related
- 1995-11-21 DE DE69535203T patent/DE69535203T2/de not_active Expired - Lifetime
- 1995-11-21 RU RU96117128A patent/RU2139046C1/ru not_active IP Right Cessation
- 1995-11-21 AT AT95936064T patent/ATE337795T1/de active
- 1995-11-21 IL IL11608195A patent/IL116081A/xx not_active IP Right Cessation
- 1995-11-21 WO PCT/IB1995/001029 patent/WO1996015815A1/en active IP Right Grant
- 1995-11-21 KR KR1019960703921A patent/KR100416163B1/ko not_active IP Right Cessation
- 1995-11-21 CN CN95191307A patent/CN1066964C/zh not_active Expired - Fee Related
- 1995-11-21 HU HU9601996A patent/HU226896B1/hu not_active IP Right Cessation
- 1995-11-21 PL PL95315585A patent/PL182989B1/pl unknown
- 1995-11-21 CA CA002178602A patent/CA2178602C/en not_active Expired - Fee Related
- 1995-11-21 AU AU38144/95A patent/AU709240B2/en not_active Ceased
- 1995-11-21 EP EP95936064A patent/EP0755270B1/en not_active Expired - Lifetime
- 1995-11-21 ES ES95936064T patent/ES2271947T3/es not_active Expired - Lifetime
- 1995-11-22 ZA ZA959941A patent/ZA959941B/xx unknown
-
1996
- 1996-07-05 NO NO19962843A patent/NO315692B1/no not_active IP Right Cessation
- 1996-07-09 MX MX9602697A patent/MX9602697A/es unknown
- 1996-07-19 FI FI962917A patent/FI120081B/sv not_active IP Right Cessation
-
2000
- 2000-06-23 US US09/599,576 patent/US6403057B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NO315692B1 (no) | 2003-10-13 |
CA2178602C (en) | 2004-03-30 |
PL182989B1 (pl) | 2002-05-31 |
IL116081A0 (en) | 1996-01-31 |
CZ214096A3 (en) | 1996-10-16 |
CN1066964C (zh) | 2001-06-13 |
WO1996015815A1 (en) | 1996-05-30 |
AU3814495A (en) | 1996-06-17 |
PL315585A1 (en) | 1996-11-12 |
HU226896B1 (en) | 2010-01-28 |
NO962843L (no) | 1996-07-05 |
DE69535203D1 (de) | 2006-10-12 |
NO962843D0 (no) | 1996-07-05 |
AU709240B2 (en) | 1999-08-26 |
CA2178602A1 (en) | 1996-05-30 |
ZA959941B (en) | 1996-06-10 |
ES2271947T3 (es) | 2007-04-16 |
HU9601996D0 (en) | 1996-09-30 |
ATE337795T1 (de) | 2006-09-15 |
RU2139046C1 (ru) | 1999-10-10 |
US6403057B1 (en) | 2002-06-11 |
FI962917A0 (sv) | 1996-07-19 |
US6333021B1 (en) | 2001-12-25 |
CZ291178B6 (cs) | 2003-01-15 |
CN1139386A (zh) | 1997-01-01 |
JPH09511762A (ja) | 1997-11-25 |
FI962917A (sv) | 1996-07-19 |
DE69535203T2 (de) | 2007-07-19 |
HUT74912A (en) | 1997-03-28 |
KR100416163B1 (ko) | 2004-03-19 |
EP0755270A1 (en) | 1997-01-29 |
IL116081A (en) | 2003-04-10 |
MX9602697A (es) | 1998-06-28 |
JP4202414B2 (ja) | 2008-12-24 |
EP0755270B1 (en) | 2006-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI120081B (sv) | Mikrokapslar, förfarande för deras framställning, och deras användning | |
US5643553A (en) | Stable microbubbles suspensions injectable into living organisms | |
US5827531A (en) | Microcapsules and methods for making | |
EP0923383A1 (en) | Novel dispersible lipid blends and uses therefor | |
JPH0240644B2 (sv) | ||
US20040258761A1 (en) | Polymer-based microcapsules and nanocapsules for diagnostic imaging and drug delivery and methods for their production | |
CZ237195A3 (en) | Contrast preparation and process for preparing thereof | |
NZ286779A (en) | Solid microcapsules with a gaseous core encapsulated in a biodegradable membrane (made from water insoluble, solid lipids); use as ultrasonic contrast agents | |
MXPA96002697A (en) | Microcapsules, manufacturing method and its | |
Morrison et al. | Microcapsules and Methods for Making |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Ref document number: 120081 Country of ref document: FI |
|
PC | Transfer of assignment of patent |
Owner name: BRACCO SUISSE S.A. |
|
MM | Patent lapsed |